PA
MRX

PharVision Advisers’s Marex Group Limited Ordinary Shares MRX Stock Holding History

PharVision Advisers’s Portfolio MRX Stock Details MRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,225
Closed -$310K – 1053
2025
Q3 		$310K Buy
9,225
+2,767
+43% +$99.9K 0.17% 209
2025
Q2 		$255K Buy
+6,458
New +$269K 0.37% 128

Other funds holding MRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $432M AUM 42.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

PharVision Advisers's MRX Position: Q4 2025 in Review

PharVision Advisers sold out of Marex Group Limited Ordinary Shares (MRX) in Q4 2025, closing a stake of 9,225 shares — an estimated $310K sold.

PharVision Advisers first reported a position in MRX in Q2 2025 and held it in 2 quarters. The position peaked at $310K in Q3 2025. 191 funds tracked by Wall St. Rank hold MRX as of Q4 2025.

  • PharVision Advisers reported no remaining Marex Group Limited Ordinary Shares position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 9,225 Marex Group Limited Ordinary Shares shares in Q4 2025, an estimated $310K.
  • PharVision Advisers first reported a position in Marex Group Limited Ordinary Shares in Q2 2025 and held it in 2 quarters.
  • PharVision Advisers's Marex Group Limited Ordinary Shares position peaked at $310K in Q3 2025.
  • 191 funds tracked by Wall St. Rank held Marex Group Limited Ordinary Shares as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.